Format

Send to

Choose Destination
J Invest Dermatol. 2014 Jul;134(7):1797-1800. doi: 10.1038/jid.2014.155.

Plasmacytoid dendritic cells in melanoma: can we revert bad into good?

Author information

1
Department of Dermatology, University Hospital of Lausanne, CHUV University Hospital, Lausanne, Switzerland.
2
Department of Dermatology, University Hospital of Lausanne, CHUV University Hospital, Lausanne, Switzerland. Electronic address: Michel.gilliet@chuv.ch.

Abstract

Tumor-infiltrating plasmacytoid dendritic cells (pDCs) promote an immunosuppressive milieu that drives tumor growth in melanoma. This phenomenon typically results from the lack of appropriate pDC activation signals in the tumor microenvironment, but it is also actively controlled by tumor cells, which have evolved strategies to inhibit type I IFN production by pDCs. In this issue, Camisaschi et al. identify a new mechanism in which tumors avoid type I IFN production by triggering LAG-3-dependent activation of pDCs. Combination therapies that restore pDC functionality and trigger innate activation to produce type I IFN should be envisaged to induce effective antitumor immunity.

PMID:
24924760
DOI:
10.1038/jid.2014.155
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center